• 대한한의학방제학회지
• /
• 제24권3호
• /
• pp.131-152
• /
• 2016

Objectives ： This study was to evaluate Sibjeondaebo-tang’s(Shiquan dabutang) effect to rat hypothyroidism which induced by 6-n-propyl-2-thiouracil(PTU)Methods ： Aqueous extracts of Sibjeondaebo-tang(Shiquan dabutang)(21.29%) were administered by oral dose of 300 and 150 mg/kg(rat’s body weight) for 42 days from 2 weeks before start of PTU treatment. During this moment the body weight, thyroid gland weights, liver weight, serum thyroid hormone, lipid content and liver antioxidant defense system were measured with histopathological changes of thyroid glands, Liver and these result were compared with LevoT₄ 0.5mg/kg treated ratsResults ： As a result of PTU treatment, marked decreases of body weight, liver weight, serum thyroid hormone levels of T₃, T₄, triglyceride content and liver CAT activation were observed with marked increases of thyroid gland weight, thyroid gland hormone TSH, activate liver H₂O₂ and SOD, serum Total cholesterol, HDL and AST amount were admitted. In addition, marked hyperplasia of follicular cells with reduce of follicular colloid contents and sizes were showed at histopathological inspections. These PTU-induces histopathological changes related to hypothyroidism were significantly reduced by treatment of both different dosages of Sibjeondaebo-tang(Shiquan dabutang).Conclusions： This study suggest that Sibjeondaebo-tang(Shiquan dabutang) extracts have favorable effect on the thyroid hormone productions with beneficial effect on hypothyroidism medicated by modulatory effects on antioxidant defense system.

• Asian Pacific Journal of Cancer Prevention
• /
• 제17권1호
• /
• pp.125-129
• /
• 2016

Background: Patients with differentiated thyroid cancers (DTC) who receive radioactive iodine-131 (RAI) are released from isolation when their dose rate is below the regulatory requirements. The purpose of this study was establish predicting factors for early release from the isolation facility after RAI administration in patients with DTC. Materials and Methods: This was a prospective study which included 96 (58 females and 38 males) patients with DTC who had received RAI from April 2013 till August 2015. The study was duly approved by the ethical committee of the institute. Patients who had complete information of primary tumor size (PTS), serum TSH, stimulated thyroglobulin level [sTg] with antibodies (IU/ml) at the time of RAI treatment were included. All had a normal serum creatinine level. To attain lower effective half-life good hydration and administration of soft laxative were ensured. Dose rate was measured (immediately, 24 h and 36 h) at 1 meter distance from anterior mid trunk and a dose rate <$50{\mu}Sv/h$ was considered as the releasing criterion. At 24 h 50 patients were released while the remaining 46 patients were released at 36 h. A post-ablative whole body scan (PA-WBIS) was performed 5-8 days after RAI ablation in all patients. Results: Patients released after 24 h were significantly younger, had smaller lesions with higher proportion of papillary cancer, lower sTg, lower sTg/TSH ratio and had received a lower dose of RAI as comapred to those who were discharged after 36 h. Serum TSH and gender were not found to have any significant correlation between two cohorts. ROC and multivariate analysis have shown age ${\leq}37years$, PTS ${\leq}3.8cm$, $RAI{\leq}150mCi$, $sTg{\leq}145ng/ml$ and $sTg/TSH{\leq}1.085$ as strong indepedent predictors for early release. Conclusions: We conclude that younger age (${\leq}37years$), smaller tumor size (${\leq}3.8cm$), lower RAI dose (${\leq}150mCi$), lower sTg (${\leq}145ng/ml$) and a lower sTg/TSH ratio (${\leq}1.085$) are significant independent predictors for release at 24 h after RAI treatment in DTC patients. Effective utilization of these factors could help the treating physicians to use limited number of internment facilities with higher throughput, lower cost and lower psychological stress to patients.

• 대한방사선기술학회지:방사선기술과학
• /
• 제36권1호
• /
• pp.11-17
• /
• 2013

최근 환자가 안심하고 진료를 받을 수 있도록 의료 환경의 변화에 따라 의료 피폭 저감화 대책이 국내, 국제적으로 추진되고 있다. 연구자는 유방촬영 시 보다 안전하게 검사를 받을 수 있도록 환자의 방사선 피폭에 대한 방어 및 안전 관리가 절실 하다고 생각되어 본 차폐체를 개발하고, 제작하게 되었다. 임상에서 사용 중인 유방촬영 장치로 SID 65 cm, 조건 28 kVp, 63 mAs, 측정기는 Victoreen 6000-529(Fluke Co.)를 이용하여 제작한 Face Block을 사용하여, 환자 30명을 대상으로 실제 갑상샘 위치에 Chamber를 놓고 CC, MLO를 촬영해 Face Block장착 전, 후 선량을 측정하였다. 그 결과 Face Block 장착 후 CC View에서 평균 65.9%의 선량이 감소되었고, MLO View에서는 평균 60.7%의 선량이 감소되었으며, 영상의 질에는 큰 변화가 없었다. 따라서 유방촬영 시 갑상샘의 피폭을 줄이고, 실용적이고, 유용한 실제 Face Block을 개발한 것에 큰 성과가 있었다고 생각되며, 유방촬영 시 환자들의 피폭에 관한 불안감을 해소시켜, 환자 만족도 증대와 함께 환자 피폭선량 경감에 크게 이바지 할 것으로 기대하며, 피폭선량을 줄일 수 있는 방안을 끊임없이 노력해야 할 것이다.

• 한국방사선학회논문지
• /
• 제16권4호
• /
• pp.471-476
• /
• 2022

전립샘암의 방사선치료법인 3D CRT와 IMRT 5 portals, IMRT 9 portals에서 정상장기인 대장과 갑상샘의 광중성자 선량 피폭으로 인하여 암이 발생할 확률을 연구하고자 한다. 전립샘암 총 처방선량 6600 cGy로 1회당 220 cGy, 총 횟수는 30회의 분할조사를 적용하였다. 실험에 사용한 의료용 선형가속기의 치료테이블(couch)위에 Rando phantom을 setup 한 후에 phantom의 대장, 갑상샘의 해당부위에 중성자 광자극발광선량계 (Optically stimulated luminescence albedo neutron dosimeter)를 위치시켜 측정하였다. 전립샘암 3D CRT시 정상장기인 대장과 갑상샘의 광중성자 선량으로 인한 2차 암의 발생확률은 10,000명 당 1.8명 이었다. 그리고 IMRT 5 portals은 10,000명 당 8.7명으로, 3D CRT에 비해서 약 5배 컸다. IMRT 9 portals는 1,000명 당 1.2명이 암이 발생할 확률이 있음의 결과를 도출하였다. 본 연구를 바탕으로 방사선 치료 시 발생하는 광중성자 선량으로 인하여 2차 방사선 피폭선량의 위험성을 연구하여, 향후 방사선의 확률적 영향과 방사선 방호에 관련하여 유용한 자료로 활용될 것으로 사료된다.

• 대한방사선기술학회지:방사선기술과학
• /
• 제31권1호
• /
• pp.11-16
• /
• 2008

목적: 갑상선 암 환자에서 방사성옥소($^{131}I$) 치료 시 체질량지수와 초기 유효선량 값의 상관관계를 알아보고, 또한 갑상선치료 환자로부터 1 m 떨어진 옆 사람에게 전달되는 유효선량 값을 측정하여 환자의 격리가 언제까지 필요한지 알아보고자 한다. 재료 및 방법: 치료당일 오전에 금식을 하게 하여 입원실에서 신장과 체중을 측정하였다. 방사성옥소($^{131}I$) 150 mCi를 환자에게 투여하기 전에 핵의학과에서 병에 들어있는 I-131 capsule을 방사선량 측정기[ATOMLAB DOSE CALIBRATORS(Biodex Medical Systems)]로 측정하여 기록 하여둔다. 치료적 용량 150 mCi(${\pm}6\;mCi$)를 투여받은 환자는 격리된 입원실에서 투여 후 바로 1 m 거리에서 초기 유효선량을 G-M survey meter로 측정하고 다음날 아침에도 같은 방법으로 선량을 측정하여 법정인 허용선량이 되면 퇴원 처방을 내고 $4{\sim}5$시간 후에 퇴원을 한다. 자료 분석은 Med calc Version 9,2,1,0통계 프로그램 이용하여 분석하였다. 결과: 초기 유효선량 값과 체질량지수 상관관계를 분석한 결과 Correlation coefficient 값이 음의 값으로 체질량지수가 증가할수록 초기 유효선량 값은 감소함을 알 수 있었다. 또한 P=0.0004로 유의한 결과임을 알 수 있었다. 체질량지수에 따른 group간의 비교를 하기위해 One-way ANOVA분석한 결과 체지방지수가 증가할수록 초기 유효선량 값이 감소하는 것을 알 수 있었다. 또한 P=0.007로 유의한 결과임을 알 수 있었다. 결론: 체질량지수와 초기선량과의 관계는 밀접한 상관관계가 있었고, 53%의 환자가 NRC규정에서 권고하는 선량을 만족시켜 1박2일 동안 입원을 하였다. 따라서 체질량지수와 초기 유효선량과의 관계를 잘 이용하게 되면 병실 회전율에 도움이 되리라 사료된다.

• 대한핵의학회지
• /
• 제1권1호
• /
• pp.67-78
• /
• 1967

Over the past 6 years, from May 1960 to June 1966, 1,716 patients with various diseases of thyroid were examined and thyroid function tests with $^{131}I$ were done. Among them, 545 patients with hyperthyroidism were treated with $^{131}I$. A summary of the clinical data of the $^{131}I$-thyroid function tests and the therapeutic results of $^{131}I$ were presented and discussed. 1. The patients examined consisted of; 596 cases(34.7%) with toxic diffuse goiter, 412 cases(24.0%) with non-toxic nodular goiter, 278 cases(16.2%) with euthyroidism, 236 cases(13.8%) with non-toxic diffuse goiter, 89 cases(5.2%) with hypothyroidism, 53 cases(3.1%) with toxic nodular goiter, 32 cases(1.9%) with thyroiditis and 20 cases(1.2%) with dyshormonogenesis. 2. There were 218(12.7%) male patients and 1,498(87.3%) female patients, showing a ratio of 1:6.9. female predominantly. 3. The majority of patients(79.6%) were in the 3rd through 5th decades of their lives showing the peak in the 4th decades(35.9%). 4. The diagnostic values and normal ranges of $^{131}I$ uptake test, 48 hour serum activity, $T_3$ red blood cell uptake and $PB^{131}I$ conversion ratio were discussed. 5. An attention was given to dyshormonogenesis, a qualitative hypothyroidism, due to its characteristic findings of clinical and $^{131}I$ thyroid function tests, and its pathogenesis was briefly reviewed. 6. Among 545 patients with hyperthyroidism treated with $^{131}I$, 68.3% was cured after single. therapeutic dose and another 24.0% was cured after second dose. 7. The complications of $^{131}I$ therapy were discussed in some details and myxedema had developed. in 3.9% of our cases. No thyroid cancer was found after $^{131}I$ therapy.

• Radiation Oncology Journal
• /
• 제31권3호
• /
• pp.162-170
• /
• 2013

Purpose: To analyze the outcome of adjuvant postoperative external beam radiotherapy (EBRT) in well-differentiated thyroid cancer (WDTC). Materials and Methods: We identified 84 patients treated with EBRT for WDTC from February 1981 to December 2010. Among them, we analyzed 39 patients who received EBRT after initial radical surgery. Twenty-four females and 15 males were included. The median age was 49 years (range, 16 to 72 years). There were 34 papillary thyroid carcinomas and 5 follicular thyroid carcinomas. Most patients showed pathologic T3/T4 stage (54%/26%). Ten patients (25.6%) had gross residual tumors. Five patients (12.8%) had tumor cells at the margin. The median EBRT dose and fraction size were 62.6 Gy and 1.8 to 2.0 Gy, respectively. Results: The median follow-up was 73 months (range, 21 to 372 months). The five-year overall survival (OS) and locoregional recurrence free survival (LRFS) were 97.4% and 86.9%, respectively. Locoregional failures occurred in 5 and all failure sites were the neck node area. In univariate analysis, OS was significantly influenced by invasion of the trachea (p = 0.016) or esophagus (p = 0.006). LRFS was significantly decreased by male (p = 0.020), gross residuum after resection (p = 0.002), close or positive tumor at surgical margin involvement (p = 0.044), and tracheal invasion (p = 0.040). No significant prognostic factor was identified in the multivariate analysis. No patient experienced the Radiation Therapy Oncology Group grade 3 or more toxicity. Conclusion: Our locoregional control rate of 87.2% is comparable to historical controls with surgery alone, even though our study had a large proportion of advanced stage. Adjuvant EBRT may an effective and safe treatment option in patients with WDTC.

• 대한한방내과학회지
• /
• 제28권2호
• /
• pp.275-283
• /
• 2007

Objective : Although hypothyroidism is a common disease in the endocrinology system, it is reported that there are a lot of difficulties in treating it effectively. Aconiti Ra얕 traditionally has been used in treatment of coldness, fatigue, and bradycardia. In this study, we investigated the therapeutic effects of Aconiti Radix on hypothyroidism rat model induced by 6-propyl-2-thiouracil (PTU). Methods : Two-month-old rats were used with administration of PTU which induced hypothyroidism in the rats. After 2 weeks, Aconiti Radix and thyroxine were administered, respectively. The body weights were measured every week. After 4 weeks, the blood samples of all rats were taken from their hearts. They were analyzed biochemically and $T_4$ (thyroid hormone) & TSH (thyroid stimulating hormone) was measured by ELISA kits. Results : In comparison with normals, controls showed hypothyroidism with significantly low $T_4$ and high TSH the statistics. In Aconiti Radix administration groups significantly increased $T_4$ was observed in the statistics and its effects were dose-dependent. There was no difference statistically in TSH of Aconiti Radix treatment groups from controls, nor were statistical differences observed significantly in biochemical labs and weight of each group. Conclusions : These findings suggest that Aconiti Radix protects thyroid cells and makes thyroid cells produce thyroid hormones. It is also very safe in the view of liver, kidney function, and other metabolism. It may be a useful agent for treating hypothyroidism.

• 동의생리병리학회지
• /
• 제19권3호
• /
• pp.623-627
• /
• 2005

Abnormal thyroid cell proliferation has a very important role in hypothyroidism. Thyroid stimulating hormone (TSH) stimulates proliferation and maintains differentiated function in thyroid follicular cells. A functioning rat thyroid cell line (FRTL) was used to study the effect of Gamgung-tang (GGT, Glycyrrhizae Radix, black beans, Angelicae Radix and Cnidii Rhizoma) on proliferation and cAMP accumulation of thyrocytes. Proliferation of cell was assessed by DNA synthesis and incorporation of $[^3H]thymidine$ into DNA. The concentration of cAMP was measured simultaneously with growth assessment. Extract of GGT ($0.15{\sim}0.9\;mg/ml$ increased DNA synthesis in a dose-dependent manner. GGT at 0.6 (p<0.05) and 0.9 mg/ml (p<0.01) significantly increased $[^3H]thymidine$ incorporation. A comparable effect was observed with TSH. GGT also enhanced cAMP accumulation. These results indicate that GGT increases the proliferation of thyrocytes and may be considered a promising agent for the treatment of autoimmune thyroid disease.

• Toxicological Research
• /
• 제17권3호
• /
• pp.203-213
• /
• 2001

We investigated the toxic effects of propylthiouracil (PTU) In Sprague-Dawley (SD) rats to develop and validate an enhanced Protocol for Test Guideline 407 as OECD Project. Twenty male and female SD rats,7 weeks old, were treated with PTU in corn oil at levels of 0, 0.1, 1 and 10 mg/kg/day for 4 weeks orally. Clinical observation, body weight changes, food uptake, water consumption, urinalysis, estrus cycle and sperm analysis, serum chemist교, autopsy findings and histopathological findings were evaluated in this study. No clinical signs and mortality were observed in the study. The body weights and food uptakes in the group treated with 10 mg/kg/day were reduced from 3 weeks after the initiation of the treatment. The levels of 3,5,3'-triiodothyronine (T3) and thyroxine (T4, 3,5,3',5'-tetraiodothyrosine) were also significantly decreased in the group treated with 10 mg/kg/day. Also, the relative and absolute organ weights of thymuses were decreased. Thyroid glands of rats in the group treated with PTU 10 mg/kg/day were bigger than those of rats in the control group. In the histopathological examination, diffuse hyperplasia and hypertrophy of thyroid follicular cells were observed in all treatment groups, leading to the reduction of lumen size and papillary enfolding of lining epithelium. The degree of lesion was increased in a dose-dependent manner. The results suggested that PTU would cause toxicity in thyroid gland and decrease the levels of T3 and T4 in SD rats. However there were no effects on the other organ including testis and uterus especially in spermatogenesis and estrus cycle. On the basis of the results, enhanced protocol for Test Guideline (TG) 407 may be sensitive and reliable to detect endocrine-active substances like PTU.